You are currently browsing the category archive for the ‘2015’ category.

The regional Neurology meeting re-opened the issue of local pathways to thrombectomy. The access to most advanced techniques seems slowed by ETS procedures and lack of full week coverage 7/7.

walter5

Anticoagulant therapy is recommended for the secondary prevention of stroke in patients with atrial fibrillation (AF). T he identification of patients at high risk for early recurrence, which are potential candidates to prompt anticoagulation, is crucial to justify the risk of bleeding associated with early anticoagulant treatment. The aim of this study was to evaluate in patients with acute ischemic stroke and AF the association between findings at trans-thoracic echocardiography (TTE) and 90 days recurrence. In consecutive patients with acute ischemic stroke and AF, TTE was performed within 7 days from hospital admission. Study outcomes were recurrent ischemic cerebrovascular events (stroke or TIA) and systemic embolism. 854 patients (mean age 76.3 ± 9.5 years) underwent a TTE evaluation; 63 patients (7.4 %) had at least a study outcome event. Left atrial thrombosis was present in 11 patients (1.3 %) among whom 1 had recurrent ischemic event. Left atrial enlargement was present in 548 patients (64.2 %) among whom 51 (9.3 %) had recurrent ischemic events. The recurrence rate in the 197 patients with severe left atrial enlargement was 11.7 %. On multivariate analysis, the presence of atrial enlargement (OR 2.13; 95 % CI 1.06-4.29, p = 0.033) and CHA2DS2-VASc score (OR 1.22; 95 % CI 1.04-1.45, p = 0.018, for each point increase) were correlated with ischemic recurrences. In patients with AF-associated acute stroke, left atrial enlargement is an independent marker of recurrent stroke and systemic embolism. The risk of recurrence is accounted for by severe atrial enlargement. TTE-detected left atrial thrombosis is relatively uncommon.

Paciaroni et AL JON 2015

Rapido

An awarness campaign in Italy by ARS and ALICE. Just developed a leaflet to help recognizing warning signs

In this touching second chapter, Francesca and Roberto take us through the ideas and actions that followed the first TED talk. How it changed and is still impacting not only their lives but also the people who are experiencing the same challange. Be parents of a child who had a prenatal stroke.

Francesca, Roberto and Mario ( their son) were first on the TED Global stage in 2013. From then on their life changed a lot and a lot of projects took life. On our stage they share their experience and achievements. From Inspiring to activate.

This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx

esoc15

As the first European Stroke Organisation Conference has drawn to a close, I want to thank all faculty members and delegates for their intellectual and practical support to the preparation and delivery of what has I believe been an outstanding success. When the overwhelming wish of our association was expressed just 11 months ago that we should establish a new conference, we barely dared to hope for 800-1,000 delegates in our first year. The reality was that 84 countries were represented in Glasgow, and that delegate numbers were close to 2,700. To accompany the presentations to a packed auditorium in our first plenary session alone there were two simultaneous online publications in the New England Journal of Medicine and one in Lancet, and we had new results presented from two additional fresh NEJM publications and an Annals of Neurology paper. In the afternoon, we heard the first multicentre, blinded RCT of an experimental approach in stroke, a stem cell RCT, the complete results of the desmoteplase programme and a further new thrombectomy trial. By the time we retired to the poster session and welcome reception, the exhibition hall was buzzing with excitement. The enthusiasm and cheerfulness were tangible, affecting everyone from the most junior researchers through to old hands. The sun shone on the entire conference, literally. I attribute the success to a huge amount of good fortune, to the efforts of a vast team and to the enthusiasm of every delegate. It would be unfair to single out any one contribution but I am convinced that it was those numerous individual contributions, offered generously and constructively, that allowed us to take advantage of the good fortune. To be present at this inaugural conference was reward enough for anyone working in stroke, because it was a once in a career occasion that we will each remember with great fondness. It was rather like a birth, a christening and a wedding, all rolled into one. Certainly, we have shown what a large and happy family we are in stroke medicine, and that Europe stands not alone but with societies and individuals all across the world. We will build on this success, we will maintain the spirit and principles that informed ESOC 2015, and I promise that by 10-12 May 2016 in Barcelona we will have another outstanding programme. For now, I express my sincere thanks to everyone for their support and hope that each of you left Glasgow with enthusiasm, new friendships and shared optimism for the future, for our patients and our specialty.

KL